Comparison of chromogenic substrates for tissue plasminogen activator and the effects on the stability of plasminogen activator inhibitor type-1

Fibrinolysis and Proteolysis

Volumn 11, Issue 5-6, 1997, Pages 287-293

  Ehnebom, J ^a   Pusa, S ^a   Bjorquist P ^a   Deinum, J ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME SUBSTRATE COMPLEX; ESCHERICHIA COLI; HALF LIFE TIME; HUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STABILITY;

EID: 0031458629     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(97)80114-2     Document Type: Article

References (24)

1. van Meijer M, Pannekoek H. Structure of plasminogen activator inhibitor type I (PAI-1) and its function in fibrinolysis: an update. Fibrinolysis 1995; 9: 263-276.
2. Abrahamsson T, Nerme V, Stromqvist M, Åkerblom B, Legnehed A, Pettersson K, Westin-Eriksson A. Anti-thrombotic effect of a PAI-1 inhibitor in rats given endotoxin. Thromb Haemost 1996; 75: 118-126.
3. Biemond BJ, Levi M, Coronel R, Janse MJ, ten Cate JW, Pannekoek H. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody. Circulation 1995; 91: 1175-1181.
4. Charlton P, Faint R, Barnes CF, Folkes A, Templeton D, Mackie I, Machin S, Bevan P. XR5118, A novel modulator of plasminogen activator inhibitor-1 (PAI-1), increases endogeneous tPA activity in the rat. Fibrinolysis & Proteolysis 1997; 11: 51-56.
5. Kvassman JO, Lawrence DA, Shore JD. The acid stabilization of plasminogen activator inhibitor-1 depends on protonation of a single group that affects loop insertion into beta-sheet A. J Biol Chem 1995; 270: 27942-27947.
6. Eitzman DT, Fay WP, Lawrence DA, Francis-Chmura AM, Shore JD, Olson ST, Ginsburg D. Peptide-mediated inactivation of recombinant and platelet plasminogen activator inhibitor-1 in vitro. J Clin Invest 1995; 95: 2416-2420.
7. Boström SL, Deinum J, Löfroth J-E, Wirth M, Kubista M. Conformational differences between latent and active plasminogen inhibitor, PAI-1: A spectroscopic study. Thromb Res 1990; 59: 851-858.
8. Lindahl TL, Sigurdardottir O, Wiman B. Stability of plasminogen activator inhibitor 1 (PAI-1). Thromb Haemost 1989; 62: 748-751.
9. Sancho F, Tonge DW, Hockney RC, Booth NA. Purification and characterization of active and stable recombinant plasminogen-activator inhibitor accumulated at high levels in Escherichia coli. Eur J Biochem 1994; 224: 125-134.
10. Seetharam R, Dwivedi AM, Duke JL, Hayman AC, Walton HL, Huckins NR, Kamerkar SM, Corman JI, Woodeshick RW, Wilk RR, Reilly TM. Purification and characterization of active and latent forms of recombinant plasminogen activator inhibitor 1 produced in Escherichia coli. Biochemistry 1992; 31: 9877-9882.
11. Reilly TM, Forsythe MS, Dwivedi AM, Walton HL, Duke JL, Wade DL, Knabb RM, Mousa SA. Vitronectin effects on recombinant plasminogen activator inhibitor-1: structural and functional analysis. Fibrinolysis 1992; 6: 167-171.
12. Declerck PJ, De Mol M, Vaughan DE, Collen D. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a non-inhibitory substrate for tissue-type plasminogen activator. J Biol Chem 1992; 267: 11693-11696.
13. Munch M, Heegaard CW, Andreasen P. Interconversions between active, inert and substrate forms of denatured/refolded type-1 plasminogen activator inhibitor. Biochim Biophys Acta 1993; 1202: 29-37
14. Sancho E, Declerck PJ, Price NC, Kelly SM, Booth NA. Conformational studies on plasminogen activator inhibitor (PAI-1) in active, latent, substrate, and cleaved forms. Biochemistry 1995; 34: 1064-1069.
15. Urano T, Strandberg L, Johansson LB-Å, Ny T. A substrate-like form of plasminogen-activator-inhibitor type 1. Eur J Biochem 1992; 209: 985-992.
16. Ehnebom J, Björquist P, Deinum J. Detergent Tween 80 modifies the specific activity of PAI-1. Fibrinolysis & Proteolysis 1997; 11: 165-170.
17. Hekman CM, Loskutoff DJ. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 1985; 260: 11581-11587.
18. Strömqvist M, Andersson J-O, Boström S, Deinum J, Ehnebom J, Enquist K, Johansson T, Hansson L. Separation of active and inactive forms of recombinant human plasminogen activator inhibitor type 1 (PAI-1) expressed in Chinese hamster ovary cells: comparison with native human PAI-1. Protein Exp Pur 1994; 5: 309-316.
19. Bjorquist P, Brohlin M, Ehnebom J, Ericsson M, Kristiansen C, Pohl G, Deinum J. Plasminogen activator inhibitor type-1 interacts exclusively with the proteinase domain of tissue plasminogen activator. Biochim Biophys Acta 1994; 1209: 191-202.
20. Strömqvist M, Andersson K-E, Björquist P, Andersson J-O, Byström M, Hansson I, Johansson T, Deinum J. Characterisation of the complex of plasminogen activator inhibitor type 1 with tissue-type plasminogen activator by mass spectrometry and size-exclusion chromatography. Biochim Biophys Acta 1996; 1295: 103-109.
21. Karlsson R, Stahlberg R. Surface plasmon resonance detection and multispot sensing for direct monitoring of interactions involving low-molecular-weight analytes and for determination of low affinities. Anal Biochem 1995; 228: 274-280.
22. Stenberg E, Persson B, Roos H, Urbaniczky C. Quantitative determination of surface concentration of protein with surface plasmon resonance by using radiolabeled proteins. Colloid and Interface Science 1991; 143: 513-526.
23. Danielsson B, Mosbach K. Analytical applications with emphasis on biosensors. Introduction. Meth Enzymol 1988; 137: 3-14.
24. Lottenberg R, Jackson CM. Solution composition dependent variation in extinction coefficients for p-nitroaniline. Biochim Biophys Acta 1983; 742: 558-564.